Merck
CN
  • Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertension.

Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertension.

Liver international : official journal of the International Association for the Study of the Liver (2014-06-11)
Jonel Trebicka, Cyrus Wix, Matthias von Heydebrand, Kanishka Hittatiya, Thomas Reiberger, Sabine Klein, Robert Schierwagen, Glen Kristiansen, Markus Peck-Radosavljevic, Hans-Peter Fischer, Søren Møller, Flemming Bendtsen, Aleksander Krag, Tilman Sauerbruch
ABSTRACT

Patients with cirrhosis display hypocontractility of splanchnic vessels because of dysregulation of vasoactive proteins, such as decreased effect of RhoA/ROCK and increased activity of β-Arrestin-2 and eNOS. However, it is unknown whether the dysregulation of vasoactive proteins is displayed in other vessels. We investigated whether expression of vasoactive proteins can be evaluated in gastric mucosa vessels. Biopsies from the gastric mucosa of 111 patients with cirrhosis were collected at three different centres and from 13 controls. Forty-nine patients had received TIPS. Portal pressure gradient was measured in 49 patients with TIPS and in 16 patients without TIPS. Biopsies from the antrum were conserved in formaldehyde for immunohistochemistry or shock-frozen for PCR and Western blot. The mucosal transcription of vascular markers (αSMA, CD31) was higher in cirrhotic patients than controls, which was confirmed by immunohistochemistry. On average, relative mucosal levels of RhoA and ROCK were lower, while β-Arrestin-2 levels were higher in cirrhotic patients compared to controls. Transcriptional levels of eNOS increased with presence of ascites and grade of oesophageal varices. Patients with TIPS showed less pronounced markers of vascular dysfunction in gastric mucosa. This is the first evidence that the expression of vasoactive proteins in mucosa from the gastric antrum of patients with cirrhosis reflects their vascular dysfunction and possibly changes after therapeutic interventions.

MATERIALS
Product Number
Brand
Product Description

L-Threonine, European Pharmacopoeia (EP) Reference Standard
Supelco
L-Threonine, Pharmaceutical Secondary Standard; Certified Reference Material
Serine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
L-Threonine, BioXtra, ≥99.5% (NT)
Supelco
L-Threonine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L-Threonine, reagent grade, ≥98% (HPLC)
Sigma-Aldrich
L-Threonine, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 99.0-101.0%
SAFC
L-Threonine
Sigma-Aldrich
DL-Serine, ≥98% (TLC)
Sigma-Aldrich
DL-Serine, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥98% (HPLC)